These data, together with our recently published data regarding MV1035 inhibition of ALKBH5 activity, provide a rationale to suggest MV1035 as a useful starting point to develop new compounds able to overcome TMZ resistance and to reduce GBM migration and invasiveness. Here, ALKBH5 is linked to glioblastoma.